PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
EBIT growth similar to AXSM's 6.72%. Walter Schloss might infer both firms share similar operational efficiencies.
7.06%
Operating income growth similar to AXSM's 6.72%. Walter Schloss would assume both share comparable operational structures.
10.36%
Net income growth 1.25-1.5x AXSM's 9.19%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
28.30%
EPS growth above 1.5x AXSM's 10.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
28.30%
Diluted EPS growth above 1.5x AXSM's 10.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
24.68%
Share count expansion well above AXSM's 0.16%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above AXSM's 0.16%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth above 1.5x AXSM's 9.15%. David Dodd would confirm a clear edge in underlying cash generation.
17.79%
FCF growth above 1.5x AXSM's 9.14%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-3628.66%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
45.61%
Positive 3Y OCF/share CAGR while AXSM is negative. John Neff might see a big short-term edge in operational efficiency.
-15204.15%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
97.68%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
59.13%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
9892.41%
Equity/share CAGR of 9892.41% while AXSM is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
293.35%
Equity/share CAGR of 293.35% while AXSM is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
201.29%
Equity/share CAGR of 201.29% while AXSM is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Positive asset growth while AXSM is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
64.49%
Positive BV/share change while AXSM is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
13.21%
We increase R&D while AXSM cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-38.56%
We cut SG&A while AXSM invests at 4.76%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.